CN105193797A - Diabetes mellitus resistant oral medicine composition - Google Patents
Diabetes mellitus resistant oral medicine composition Download PDFInfo
- Publication number
- CN105193797A CN105193797A CN201510766817.4A CN201510766817A CN105193797A CN 105193797 A CN105193797 A CN 105193797A CN 201510766817 A CN201510766817 A CN 201510766817A CN 105193797 A CN105193797 A CN 105193797A
- Authority
- CN
- China
- Prior art keywords
- base
- azetidine
- cyclopropyl
- methoxynaphthalene
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a diabetes mellitus resistant medicine composition. The medicine composition comprises the following components: (1) 10-20mg of 5-(3-hydroxy-7-methoxy naphthalene-2-yl)-1,1-dioxo-[1,2,5]thiadiazolidine-3-one potassium salt, (2) 20-30mg of (2S,3R)-3-((R)-3-(1-(2,5-bis(trifluoromethyl)benzyl)-azetidine-3-yl)-2,3-dihydrobenzo[b][1,4]dioxy heterocyclohexadiene-6-yl)-3-cyclopropyl-2-methyl propionic acid, (3) 200-300mg of microcrystalline cellulose, (4) 10-25mg of croscarmellose sodium and (5) 1-8mg of magnesium stearate. The usage amount of active matters of the medicine is reduced by at least 1/2 under the premise of achieving the same treatment effects by compounding two different types of active matters.
Description
Technical field
The present invention relates to medical art, be specifically related to a kind of diabetes combination of oral medication.
Background technology
The metabolic disease of diabetes to be one group with hyperglycemia be feature.Hyperglycemia be then due to defect of insulin secretion or its biological agent impaired, or both have concurrently and cause.Long-standing hyperglycemia during diabetes, causes various tissue, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction.
The generally acknowledged form of usual existence two kinds of diabetes.In type 1 diabetes or insulin-dependent diabetes (IDDM), patient produces seldom or does not have insulin, regulates the hormone of glucose application.In type 2 diabetes mellitus or noninsulindependent diabetes (NIDDM), still produce insulin in the body.There is in the stimulation glucose of the patient suffering from type 2 diabetes mellitus in main insulin-sensitive tissue (it is muscle, liver and fatty tissue) and lipid metabolism the toleration to insulin action.These patients have the insulin of common level usually, and may have hyperinsulinemia (plasma insulin level of rising), because they compensate by the insulin of secretion rise the insulin effects reduced.Insulin resistance can not be caused by the Insulin receptor INSR reducing quantity but be caused by the rear Insulin receptor INSR binding deficient understood not yet completely substantially.This lacks and to cause in the oxidation of glucose in the activation of the insulin-mediated of inadequate picked-up, muscle and storage and fatty tissue glucose in lipidolysis and liver to produce to the responding ability of insulin and the suppression of insufficient insulin-mediated of secretion.
Current Remedies for diabetes is maintaining treatment effect, many employing 100mg active matter oral doses, and needs daily repeatedly to take.Due to the side effect of active matter, other health hazards are caused to patient, meanwhile, due to the increase of dosage, also make medicine cost increase, cause the raising for the treatment of cost.
Summary of the invention
The object of the invention is to propose a kind of diabetes combination of oral medication, its composite by two kinds of dissimilar active matters, under the prerequisite reaching identical therapeutic effect, the use amount of the active matter of medicine is reduced at least 1/2.
For reaching this object, the present invention by the following technical solutions:
A kind of diabetes combination of oral medication, it comprises following component:
(1) 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 10-20mg
(2) (the 2S of 20-30mg, 3R)-3-((R)-3-(1-(2, two (trifluoromethyl) benzyl of 5-)-azetidine-3-base)-2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] Dioxin-6-base)-3-cyclopropyl-2 Methylpropionic acid
(3) 200-300mg microcrystalline Cellulose,
(4) 10-25mg cross-linking sodium carboxymethyl cellulose, and
(5) 1-8mg magnesium stearate.
Described 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt and (2S, 3R)-3-((R)-3-(1-(2, two (trifluoromethyl) benzyl of 5-)-azetidine-3-base)-2,3-dihydrobenzos [b] [Isosorbide-5-Nitrae] Dioxin-6-base) ratio of-3-cyclopropyl-2 Methylpropionic acid is less than 1.
Detailed description of the invention
The present invention is described pharmaceutical composition of the present invention by following embodiment.
Embodiment 1
I.5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt
Step 1
3-benzyloxy-7-methoxynaphthalene-2-benzyl formate
5.0g (21.7mmol) 3-hydroxyl-7-methoxynaphthalene-2-formic acid, 9.29g (54.3mmol) benzyl bromide a-bromotoluene and the mixture of 9.01g (65.2mmol) potassium carbonate in 25mLDMF are stirred 24 hours in 60 DEG C.After being cooled to room temperature, by mixture impouring water, be extracted in EtOAc.Organic facies is washed with 3 × water and 1 × saturated NaCl.Use dried over sodium sulfate organic facies, under reduced pressure except desolventizing.Making residual solid crystallization from dichloromethane/ethanol, obtain title compound, is Tan solid, mp96-98 °.
H-NMR (CDCl): δ 8.25 (s, 1H), 7.61 (d, J=8.83Hz, 1H), 7.49 (d, J=7.35Hz, 2H), 7.46-7.30 (m, 7H), 7.24 (d, J=5.88Hz, 2H), 7.18 (dd, J=9.20 and 2.58Hz, 1H), 7.12 (m, 1H), 5.40 (s, 2H), 5.23 (s, 2H), 3.89 (s, 3H). analyze: CHO: value of calculation C, 78.38; H, 5.57. measured value C, 78.28; H, 5.56.
Step 2
3-benzyloxy-7-methoxynaphthalene-2-formic acid
In the suspension of 6.07g (20mmol) 3-benzyloxy-7-methoxynaphthalene-2-benzyl formate in 100mL ethanol, add 24mL1.0NNaOH (1.2 equivalent), mixture is stirred 4 hours in 60 DEG C, in stirring at room temperature 16 hours.Under reduced pressure except desolventizing, residual solid is dissolved in 50mL water.Use washed with diethylether solution, with 2NHCl acidify aqueous phase.Filtration gained precipitates, and washes with water, and dry, obtaining title compound, is faint yellow solid.
Mp177-179 ° of .H-NMR (CDCl): δ 11.01 (s, wide, 1H), 8.70 (s, 1H), 7.67 (d, J=8.82Hz, 1H), 7.53-7.41 (m, 5H), 7.37 (s, 1H), 7.27 (dd, J=8.83 and 2.57Hz, 1H), 7.20 (m, 1H), 5.36 (s, 2H), 3.92 (s, 3H). analyze: CHO: value of calculation C, 74.01; H, 5.23. measured value C, 73.71; H, 5.46.
Step 3
(3-benzyloxy-7-methoxynaphthalene-2-base)-t-butyl carbamate
In the suspension of the anhydrous t-BuOH+40mL dry toluene of 40mL, 2.3g (22mmol) triethylamine is added to 4.6g (14.9mmol) 3-benzyloxy-7-methoxynaphthalene-2-formic acid.In gained solution, add 5.34g (19.4mmol) DPPA, by mixture in stirring at room temperature 5 minutes, then stir 18 hours in 100 DEG C.Mixture is cooled to room temperature, then in impouring water.Mixture extraction is entered in EtOAc, wash organic facies with saturated NaCl.Under reduced pressure except desolventizing, residue uses hexane/ethyl acetate (85: 15) to carry out purification by flash chromatography, elutes title compound, is grease, slowly becomes waxy solid.
H-NMR(CDCl)：δ8.48(s，1H)，7.50(d，J＝8.82Hz，1H)，7.48-7.31(m，7H)，7.10(s，1H)，6.99(dd，J＝8.82and2.57Hz，1H)，5.17(s，2H)，3.84(s，3H)，1.54(s，9H).
Step 4
3-benzyloxy-7-methoxynaphthalene-2-base amine
By 4.99g (13.1mmol) (3-benzyloxy-7-methoxynaphthalene-2-base) solution of-t-butyl carbamate in 50mLTFA/ dichloromethane (1: 1) in stirring at room temperature 30 minutes.Under reduced pressure except desolventizing, 10% sodium bicarbonate aqueous solution is joined in residue.Mixture extraction is entered in EtOAc, use dried over sodium sulfate organic facies.Under reduced pressure except desolventizing, residue uses dichloromethane to carry out purification by flash chromatography, elutes title compound, makes its crystallization from ethanol, obtain white solid,
Mp149-151 ° of .H-NMR (CDCl): δ 7.54-7.32 (m, 6H), 7.09 (s, 1H), 6.92 (d, J=9.20Hz, 2H), 6.89 (dd, J=8.82 and 2.57Hz, 1H), 5.18 (s, 2H), 4.11 (s, wide, 2H), (3.87 s, 3H).
Step 5
(3-benzyloxy-7-methoxynaphthalene-2-base is amino)-methyl acetate
2.26g (14.8mmol) methyl bromoacetate is added in 2.76g (9.88mmol) 3-benzyloxy-7-methoxynaphthalene-2-base amine and the mixture of 2.73g (19.8mmol) potassium carbonate in 20mLDMF.Mixture is stirred 2 hours in 60 DEG C, then in stirring at room temperature 16 hours.By in mixture impouring water, be extracted in EtOAc.Wash organic facies with water (3 ×), saturated NaCl (1 ×), use dried over sodium sulfate.Under reduced pressure except desolventizing, making residue crystallization from ethanol, obtain title compound, is pale solid,
Mp129-131 °.; NMR (CDCl): δ 7.50 (s, wide, 2H), (7.49 d, J=8.46Hz, 1H), 7.45-7.33 (m, 3H), 7.07 (s, 1H), 6.97 (d, J=2.20Hz, 1H), 6.89 (dd, J=8.82 and 2.57Hz, 1H), 6.62 (s, 1H), 5.20 (s, 3H), 4.05 (s, 2H), 3.88 (s, 3H), 3.80 (s, 3H) .MS (M+1): 352. analyze: CHNO: value of calculation C, 71.78; H, 6.02; N, 3.99. measured value C, 71.61; H, 5.86; N, 3.91.
Step 6
N-(tertbutyloxycarbonyl sulfamoyl)-N-(3-benzyloxy-7-methoxyl group naphthyl) glycine methyl ester
The solution of 649mg (8.76mmol) tert-butyl alcohol in 3mL dichloromethane is dripped in the solution of 1.24g (8.77mmol) Carbimide. chlorine sulfonyl ester in 25mL dichloromethane.By solution in stirring at room temperature 30 minutes, then drip 2.2g (6.26mmol) (3-benzyloxy-7-methoxynaphthalene-2-base is amino)-methyl acetate and the solution of 1.27g (12.6mmol) triethylamine in 25mL dichloromethane.By mixture in stirring at room temperature 90 minutes, then wash with water.Use dried over sodium sulfate organic facies, under reduced pressure except desolventizing.Residual oil thing uses hexane/ethyl acetate (70: 30) to carry out purification by flash chromatography, elutes title compound, is grease.
H-NMR (CDCl): δ 8.10 (s, 1H), 7.68 (s, wide, 1H), 7.54 (d, J=9.80Hz, 1H), 7.49-7.29 (m, 5H), 7.17 (s, 1H), 7.14-7.08 (m, 2H), 5.23 (s, 2H), 4.63 (s, 2H), 3.86 (s, 3H), 3.68 (s, 3H), 1.41 (s, 9H) .MS (M-1): 529.
Step 7
N-sulfamoyl-N-(3-benzyloxy-7-methoxyl group naphthyl) glycine methyl ester
By 3.1g (5.85mmol) N-(tertbutyloxycarbonyl sulfamoyl)-N-(3-benzyloxy-7-methoxyl group naphthyl) solution of glycine methyl ester in 40mL trifluoroacetic acid/dichloromethane (1: 1) in stirring at room temperature 30 minutes.Under reduced pressure except desolventizing.Joined by dichloromethane in residue, then under reduced pressure (4x) removing, obtaining oily solid, it ground together with ether (16 hours), obtain title compound, is solid,
Mp137-139 °; H-NMR (CDCl): δ 8.01 (s, 1H), 7.58 (d, J=8.83Hz, 1H), 7.51-7.32 (m5H), 7.23-7.05 (m, 3H), 5.17 (s, wide, 2H), 5.15 (s, 2H), 4.39 (s, 2H), 3.85 (s, 3H), 3.67 (s, 3H) .MS (M+1): 431. analyze: CHNOS: value of calculation C, 58.59; H, 5.15; N, 6.51. measured value C, 58.53; H, 5.05; N, 6.62.
Step 8
5-(3-benzyloxy-7-methoxynaphthalene-2-base)-1; 1-dioxo-[1; 2,5] thiadiazolidine-3-ketone potassium salt drips the solution of 4.4mL1.0M potassium tert-butoxide in THF in 1.89g (4.39mmol) N-sulfamoyl-N-(3-benzyloxy-7-methoxyl group naphthyl) solution of glycine methyl ester in 5mLTHF.By mixture in stirring at room temperature 18 hours.Filter the dense thick precipitation of gained, wash with the THF of small size.Drying under reduced pressure solid, obtains title compound, mp182-198 °.
Step 9
5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt
By 1.75g (4.01mmol) 5-(3-benzyloxy-7-methoxynaphthalene-2-base)-1, the 1-dioxo-solution of [1,2,5] thiadiazolidine-3-ketone potassium salt in 150mL water on 500mg10%Pd/C in 50psi hydrogenation 24 hours.Leach catalyst, with ethyl acetate washing containing filter liquor.By aqueous phase lyophilization, obtaining title compound, is light brown amorphous solid.
Mp260-265 ° of H-NMR (DMSO-d:7.90 (s, 1H), 7.54 (d, J=9.04Hz, 1H), 7.14 (s, 1H), 7.12 (d, J=2.64Hz, 1H), 6.98 (dd, J=9.04 and 2.64Hz, 1H), 4.20 (s, 2H), 3.81 (s, 3H) .MS (M-1): 307.
II. (2S, 3R)-3-((R)-3-(1-(2, two (trifluoromethyl) benzyl of 5-)-azetidine-3-base)-2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] Dioxin-6-base)-3-cyclopropyl-2 Methylpropionic acid
(2S, 3R)-3-((R)-3-(1-((R)-1-(2, two (trifluoromethyl) phenyl of 5-) ethyl) azetidine-3-base)-2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] Dioxin-6-base)-3-cyclopropyl-2 Methylpropionic acid
Steps A: divide several parts to 3-vinyl azetidine-1-formic acid esters (1.75g, 9.6mmol) be suspended in the agitating solution in-BuOH (37.00mL) and HO (37.00mL) and add AD-MIX-ALPHA (13.4g, 9.6mmol, SigmaAldrich).Stir this reaction 20h at ambient temperature, then with HO dilution, and extract with EtOAc.With the organic extract that saline (1x) washing merges, dry through MgSO, filter, and concentrate under vacuo.Use the gradient-purified gained residue of 0-100%EtOAc/ hexane to provide (S)-3-(1,2-dihydroxy ethyl) azetidine-1-formic acid esters by silica gel column chromatography (ISCO system, RediSep40g post).
Step B: to (S)-3-(1,2-dihydroxy ethyl) azetidine-1-formic acid esters (1.9g, imidazoles (0.6g is added in solution 8.8mmol) in CHCl (25mL), 8.8mmol) with chlorodiphenyl base silane (2.2mL, 8.8mmol).Stirring at ambient temperature after 20 minutes, filtering gained precipitate and concentrated filtrate under vacuo by crossing.0-65%EtOAC/ hexane is used as the gradient-purified gained residue of eluent to provide (S)-3-(2-((diphenylsilyl group) oxygen base)-1-hydroxyethyl) azetidine-1-t-butyl formate by silica gel column chromatography (ISCO system, RediSep80g post).
Step C: to (S)-3-(2-((diphenylsilyl group) oxygen base)-1-hydroxy-ethyl) azetidine-1-t-butyl formate (0.39g at-50 DEG C, TEA (0.18mL is added in solution 0.9mmol) in CHCl (5mL), 1.3mmol) with MsCl (0.1mL, 1.2mmol).After 20min, adopt this reaction of saturated NHCl aqueous solution cancellation and make it be warmed to room temperature.Then organic layer is separated; dry through MgSO; filter and concentrate to provide (S)-3-(2-((diphenylsilyl group) oxygen base)-1-methylsulfonylethyl) azetidine-1-t-butyl formate, it uses immediately in the next step.
Step D: by (2S; 3R)-3-cyclopropyl-3-(3-hydroxyl-4-iodophenyl)-2 Methylpropionic acid methyl ester (68mg; 0.19mmol); CsCO (122mg; 0.3mmol) be heated to 65 DEG C of lasting 12h with ()-3-(2-((diphenylsilyl group) oxygen base)-1-methylsulfonylethyl) agitating solution of azetidine-1-t-butyl formate (100mg, 0.19mmol) in DMF (2mL).Then wash this reactant mixture with HO, and extract with EtOAc (3x50mL).With the organic layer that salt water washing merges, dry through MgSO, filter, and it is concentrated to provide crude product, it is by ISCO (4g, 0-20%EtOAc/ hexane) purification to be to provide 3-((R)-2-((t-butyldiphenylsilyl) oxygen base)-1-(5-((1R, 2S)-1-cyclopropyl-3-methoxyl group-2-methyl-3-oxopropyl)-2-iodine phenoxy group) ethyl) azetidine-1-formic acid esters.LC/MS：m/e798.92(M+H)
+。
Step e: to 3-((R)-2-((t-butyldiphenylsilyl) oxygen base)-1-(5-((1R, 2S)-1-cyclopropyl-3-methoxyl group-2-methyl-3-oxopropyl)-2-iodine phenoxy group) ethyl) azetidine-1-formic acid esters (45mg, TBAF (0.1mL is dropwise added in solution 0.06mmol) in THF (6mL), 0.1mmol, 1M are in THF).Stir this reaction 30min, then pour in EtOAc and HO with the cancellation of saturated NHCl aqueous solution.Be separated each layer, and with the organic layer that salt water washing merges, dry through MgSO, filter, and be concentrated under vacuo on silica gel.By column chromatography (ISCO system, RediSep24g post) use 0-30-80%EtOAc/ hexane as the gradient-purified crude product of eluent to provide 3-((R)-1-(5-((1R, 2S)-1-cyclopropyl-3-methoxyl group-2-methyl-3-oxopropyl)-2-iodine phenoxy group)-2-hydroxyethyl) azetidine-1-formic acid esters.LC/MS：m/e560.72(M+H)
+。
Step F: purge 3-((R)-1-(5-((1R with N, 2S)-1-cyclopropyl-3-methoxyl group-2-methyl-3-oxopropyl)-2-iodine phenoxy group)-2-hydroxyethyl) azetidine-1-formic acid esters (113mg, 0.2mmol), Pd (OAc) (4.5mg, 0.02mmol), Trixiephos (16mg, 0.02mmol, Strem), with CsCO (132mg, solution 0.4mmol) in toluene (4mL) 10 minutes, is then heated to 50 DEG C of lasting 14h under N.Then, cool this reaction, and dilute with EtOAc.Be separated organic layer, with HO and saline (2x) washing, dry through MgSO, filter, and concentrate under vacuo.By silica gel column chromatography (ISCO system, RediSep24g post) use 0-30%EtOAc/ hexane as the gradient-purified gained residue of eluent to provide 3-((R)-7-((1R, 2S)-1-cyclopropyl-3-methoxyl group-2-methyl-3-oxopropyl)-2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] Dioxin-2-base) azetidine-1-formic acid esters.LC/MS：m/e432.69(M+H)
+。
Step G: at room temperature to 3-((R)-7-((1R, 2S)-1-cyclopropyl-3-methoxyl group-2-methyl-3-oxopropyl)-2,3-dihydrobenzo [b] [1,4] Dioxin-2-base) azetidine-1-formic acid esters (120mg, TFA (0.2mL, 2.63mmol) is added in solution 0.3mmol) in DCM (5mL).At room temperature stir gained solution 3h, then by being concentrated into dry to provide (2S with methylbenzene azeotropic, 3R)-3-((R)-3-(azetidine-3-base)-2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] Dioxin-6-base)-3-cyclopropyl-2 Methylpropionic acid methyl ester.LC/MS：m/e446.43(M+H)
+。
Step H: at room temperature to (2S, 3R)-3-((R)-3-(azetidine-3-base)-2,3-dihydrobenzo [b] [1,4] Dioxin-6-base)-3-cyclopropyl-2 Methylpropionic acid methyl ester (114mg, (R)-1-(2 is added in solution 0.3mmol) in acetonitrile (3mL), two (trifluoromethyl) phenyl of 5-) ethyl methane sulfonate ester (114mg, 0.4mmol) with CsCO (300mg, 0.9mmol).At 60 DEG C, stir this reaction 12h, then with HO dilution, and extract with EtOAc (3x10mL).With the organic layer that saline (3x10mL) washing merges, dry through MgSO, filter, concentrated.By MPLC (ISCO, 4g, 0-50%EtOAc/ hexane) purification of crude product to be to provide (2S, 3R)-3-((R)-3-(1-((R)-1-(2, two (TRIFLUORO-METHYL) phenyl of 5-) ethyl) azetidine-3-base)-2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] Dioxin-6-base)-3-cyclopropyl-2 Methylpropionic acid methyl ester.LC/MS：m/e572.63(M+H)
+。
Step I: at room temperature to (2S, 3R)-3-((R)-3-(1-((R)-1-(2, two (the trifluoromethyl)-phenyl of 5-) ethyl) azetidine-3-base)-2,3-dihydrobenzo [b] [1,4] Dioxin-6-base) add LiOH in the solution of-3-cyclopropyl-2 Methylpropionic acid methyl ester (84mg, 0.1mmol) in THF (0.75ml)/MeOH (0.75ml)/water (0.5ml).At 55 DEG C, stir this reaction 12h, then with HO dilution, and become pH4-5 with 1NHCl acidify.This reactant mixture is extracted with EtOAc (3x).With the organic layer that salt water washing merges, dry through MgSO, filter, and concentrated to provide crude product, it passes through ISCO (4g, 0-100%EtOAc/ hexane) purification to provide (2S, 3R)-3-((R)-3-(1-(2, two (trifluoromethyl) benzyl of 5-)-azetidine-3-base)-2,3-dihydrobenzos [b] [Isosorbide-5-Nitrae] Dioxin-6-base)-3-cyclopropyl-2 Methylpropionic acid.
1hNMR (500MHz, acetone): δ (ppm) 0.01 (m, 1H); 0.26 (m, 2H); 0.57 (m, 1H); 0.93 (d, J=6.9Hz, 1.12 (m, 1H); 1.25-1.21 (m, 3H); 1.97 (m, 1H); 2.74 (m, 2H); 3.27-3.18 (m, 2H); 3.50-3.44 (m, 1H); 3.89-3.78 (m, 2H); (4.06 q, J=7.1Hz, 1H); 4.35-4.28 (m, 2H); 6.79-6.70 (m, 3H); (7.82 t, J=7.1Hz, 1H); (7.95 t, J=7.8Hz, 1H); (8.27 s, 1H).
By the component I for preparing and II, obtain described diabetes combination of oral medication according to following dosage is composite:
(1) 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 15mg
(2) (the 2S of 30mg, 3R)-3-((R)-3-(1-(2, two (trifluoromethyl) benzyl of 5-)-azetidine-3-base)-2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] Dioxin-6-base)-3-cyclopropyl-2 Methylpropionic acid
(3) 268mg microcrystalline Cellulose,
(4) 20mg cross-linking sodium carboxymethyl cellulose, and
(5) 5mg magnesium stearate.
The bull C57BLob/ob mice in 11 week age is housed in reverse smooth circular chamber (from 6:00p.m. to 6:00a.m. illumination) with 6/cage, arbitrarily edible Purina Rodent Meal and drinking-water.At the 1st day, get tail blood sample at 8:00am, measure plasma glucose levels.Animal is randomized into matched group and compound group.The meansigma methods of the plasma glucose levels of each group is mated.Then the Orally administered solvent of animal (there is 0.5% carboxymethyl cellulose of 0.2% tween 80) or the compound (30mg/kg) in solvent is given.Every day, to mice administration, amounts to 3 days.At the 4th day, get basal blood specimens.Adopt the concentration of glucose of YSI2700 dual pathways biochemistry analyzer (YellowSpringsInstrumentCo., YellowSprings, OH) analysed for plasma sample, adopt ELISA algoscopy to measure insulin concentration.Test result shows, its concentration of glucose is 80-120mg/dL, its insulin concentration: 4.4 ~ 8.0mmol/L.
Comparative example 1
Containing the component I of 100mg, not containing component I I, all the other conditions are constant, and its concentration of glucose and insulin concentration are all in the scope of embodiment 1.
Comparative example 2
Containing the component I of 50mg, not containing component I I, all the other conditions are constant, and its concentration of glucose is greater than 150mg/dL.
Comparative example 3
Containing the component I I of 100mg, not containing component I, all the other conditions are constant, and its concentration of glucose and insulin concentration are all in the scope of embodiment 1.
Comparative example 4
Containing the component I I of 50mg, not containing component I, all the other conditions are constant, and its concentration of glucose is greater than 150mg/dL.
Above-described embodiment and comparative example explanation, diabetes combination of oral medication of the present invention, it is composite by two kinds of dissimilar active matters, under the prerequisite reaching identical therapeutic effect, the use amount of the active matter of medicine is reduced at least 1/2, when two kinds of active matters that the present invention adopts are used alone, within the scope of equal volume, glucose in blood cannot be reduced in normal range of the present invention, prove to create cooperative effect between two kinds of active matters that the present invention adopts.
Applicant states, the present invention illustrates diabetes combination of oral medication of the present invention by above-described embodiment, but the present invention is not limited to above-mentioned specific components and formula, does not namely mean that the present invention must rely on above-mentioned detailed component and formula could be implemented.Person of ordinary skill in the field should understand, any improvement in the present invention, to equivalence replacement and the interpolation of auxiliary element, the concrete way choice etc. of each raw material of product of the present invention, all drops within protection scope of the present invention and open scope.
Claims (2)
1. a diabetes combination of oral medication, it comprises following component:
(1) 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 10-20mg
(2) (the 2S of 20-30mg, 3R)-3-((R)-3-(1-(2, two (trifluoromethyl) benzyl of 5-)-azetidine-3-base)-2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] Dioxin-6-base)-3-cyclopropyl-2 Methylpropionic acid
(3) 200-300mg microcrystalline Cellulose,
(4) 10-25mg cross-linking sodium carboxymethyl cellulose, and
(5) 1-8mg magnesium stearate.
2. diabetes combination of oral medication as claimed in claim 1, it is characterized in that, described 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt and (2S, 3R)-3-((R)-3-(1-(2, two (trifluoromethyl) benzyl of 5-)-azetidine-3-base)-2,3-dihydrobenzo [b] [Isosorbide-5-Nitrae] Dioxin-6-base) ratio of-3-cyclopropyl-2 Methylpropionic acid is less than 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510766817.4A CN105193797A (en) | 2015-11-11 | 2015-11-11 | Diabetes mellitus resistant oral medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510766817.4A CN105193797A (en) | 2015-11-11 | 2015-11-11 | Diabetes mellitus resistant oral medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105193797A true CN105193797A (en) | 2015-12-30 |
Family
ID=54941992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510766817.4A Pending CN105193797A (en) | 2015-11-11 | 2015-11-11 | Diabetes mellitus resistant oral medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105193797A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687828A (en) * | 2007-06-04 | 2010-03-31 | 诺瓦提斯公司 | Thiadiazole derivatives as antidiabetic agents |
| CN104994848A (en) * | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
-
2015
- 2015-11-11 CN CN201510766817.4A patent/CN105193797A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687828A (en) * | 2007-06-04 | 2010-03-31 | 诺瓦提斯公司 | Thiadiazole derivatives as antidiabetic agents |
| CN104994848A (en) * | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100457730C (en) | Indoles having anti-diabetic activity | |
| CN103080104B (en) | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein | |
| CN103415519B (en) | As 6,7-dihydro-pyrazol [1, the 5-a] pyrazine-4-yl amine derivatives that beta-secretase (BACE) inhibitor is useful | |
| DE60225561T2 (en) | INDANIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES AND METHOD OF PREPARING THEM | |
| CN102395567A (en) | Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity | |
| CN108329253A (en) | Preceding neurogenic compounds | |
| TWI749024B (en) | Compounds and their use for reducing uric acid levels | |
| CN105209039B (en) | LXR conditioning agents | |
| CN107652239A (en) | N substituted imidazoles carboxylic acid ester compound, Preparation method and use | |
| CN105980381A (en) | Substituted uracils and use thereof | |
| JPH01211582A (en) | Benzodioxole derivative | |
| CN105193797A (en) | Diabetes mellitus resistant oral medicine composition | |
| CN101087757B (en) | Novel dipeptidyl peptidase iv inhibitors, process for their preparation and compositions containing them | |
| CN105412095A (en) | Anti-diabetes oral drug composition | |
| CN105232546A (en) | Anti-diabetic oral drug composition | |
| CN105213381A (en) | A kind of diabetes combination of oral medication | |
| CN105250277A (en) | Orally-administered drug composition for resisting diabetes | |
| CN105213384A (en) | A kind of diabetes combination of oral medication | |
| CN105232552A (en) | Anti-diabetic oral drug composition | |
| CN105520943A (en) | Anti-diabetics oral pharmaceutical composition | |
| CN105434433A (en) | Antidiabetic oral drug composition | |
| CN105213382A (en) | A kind of diabetes combination of oral medication | |
| CN105287535A (en) | Anti-diabetes oral pharmaceutical composition | |
| CN105213385A (en) | A kind of diabetes combination of oral medication | |
| CN103012314B (en) | Sulfonamide compound and preparation method as well as application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151230 |